Protein Deimination in Human Health and Disease [electronic resource] / edited by Anthony P. Nicholas, Sanjoy K. Bhattacharya, Paul R. Thompson.

Інтелектуальна відповідальність: Вид матеріалу: Текст Публікація: Cham : Springer International Publishing : Imprint: Springer, 2017Видання: 2nd ed. 2017Опис: IX, 474 p. 116 illus., 81 illus. in color. online resourceТип вмісту:
  • text
Тип засобу:
  • computer
Тип носія:
  • online resource
ISBN:
  • 9783319582443
Тематика(и): Додаткові фізичні формати: Printed edition:: Немає назви; Printed edition:: Немає назви; Printed edition:: Немає назвиДесяткова класифікація Дьюї:
  • 612.8 23
Класифікація Бібліотеки Конгресу:
  • RC321-580
Електронне місцезнаходження та доступ: У: Springer eBooksЗведення: Published in 2014,  Protein Deimination in Human Health and Disease  was the first book on this novel post-translational modification, in which selected positively-charged arginine amino acids are converted to neutral citrulline amino acids by the peptidyl-arginine deiminase (PAD) family of enzymes. This area of research continues to expand rapidly, necessitating the need for this second edition. Chronicling the latest inflammatory, epigenetic, neurodegenerative, and carcinogenic processes,  Protein Deimination in Human Health and Disease, Second Edition, updates the latest advances in deimination research, including new information on PAD enzyme structure and activity, and how PAD knock-out animals are being used to study known and newly-discovered links to various human diseases. The first edition outlined what was known about citrullinated proteins in normal tissues such as skin and hair, as well as in maladies such as rheumatoid arthritis (RA), multiple sclerosis (MS), Alzheimer’s disease (AD), glaucoma, peripheral nerve injury, neonatal hypoxic brain damage, and breast cancer. This second edition addresses numerous additional disorders such as diabetes, asthma, traumatic brain injury, inflammatory bowel disease, lupus, bone disease, heart failure, fronto-temporal dementia, and prostate and colon cancer. It also provides updates on the deimination research covering the three seminal diseases first linked to this process (RA, MS and AD), and details how auto-antibodies against citrullinated proteins contribute to disease. In addition, new hypotheses on the possible pathologic mechanisms of citrullinated myelin basic protein and glial fibrillary acidic protein are also proposed. This second edition also outlines the latest developments in therapeutic strategies, including the use of new PAD antagonists and innovative techniques such as micro-vescicles and stem cells as possible mechanisms to treat these conditions.
Тип одиниці: ЕКнига Списки з цим бібзаписом: Springer Ebooks (till 2020 - Open Access)+(2017 Network Access)) | Springer Ebooks (2017 Network Access))
Мітки з цієї бібліотеки: Немає міток з цієї бібліотеки для цієї назви. Ввійдіть, щоб додавати мітки.
Оцінки зірочками
    Середня оцінка: 0.0 (0 голос.)
Немає реальних примірників для цього запису

Published in 2014,  Protein Deimination in Human Health and Disease  was the first book on this novel post-translational modification, in which selected positively-charged arginine amino acids are converted to neutral citrulline amino acids by the peptidyl-arginine deiminase (PAD) family of enzymes. This area of research continues to expand rapidly, necessitating the need for this second edition. Chronicling the latest inflammatory, epigenetic, neurodegenerative, and carcinogenic processes,  Protein Deimination in Human Health and Disease, Second Edition, updates the latest advances in deimination research, including new information on PAD enzyme structure and activity, and how PAD knock-out animals are being used to study known and newly-discovered links to various human diseases. The first edition outlined what was known about citrullinated proteins in normal tissues such as skin and hair, as well as in maladies such as rheumatoid arthritis (RA), multiple sclerosis (MS), Alzheimer’s disease (AD), glaucoma, peripheral nerve injury, neonatal hypoxic brain damage, and breast cancer. This second edition addresses numerous additional disorders such as diabetes, asthma, traumatic brain injury, inflammatory bowel disease, lupus, bone disease, heart failure, fronto-temporal dementia, and prostate and colon cancer. It also provides updates on the deimination research covering the three seminal diseases first linked to this process (RA, MS and AD), and details how auto-antibodies against citrullinated proteins contribute to disease. In addition, new hypotheses on the possible pathologic mechanisms of citrullinated myelin basic protein and glial fibrillary acidic protein are also proposed. This second edition also outlines the latest developments in therapeutic strategies, including the use of new PAD antagonists and innovative techniques such as micro-vescicles and stem cells as possible mechanisms to treat these conditions.

Available to subscribing member institutions only. Доступно лише організаціям членам підписки.

Online access from local network of NaUOA.

Online access with authorization at https://link.springer.com/

Онлайн-доступ з локальної мережі НаУОА.

Онлайн доступ з авторизацією на https://link.springer.com/

Немає коментарів для цієї одиниці.

для можливості публікувати коментарі.